AIM ImmunoTech Inc. (AIM)
USD 0.2
(-6.89%)
USD 0.2
(-6.89%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 160 Thousand USD | 100.81% |
| 2022 | -19.78 Million USD | -2666.71% |
| 2021 | -715 Thousand USD | -11.2% |
| 2020 | -643 Thousand USD | 14.61% |
| 2019 | -753 Thousand USD | -45.65% |
| 2018 | -517 Thousand USD | 30.7% |
| 2017 | -746 Thousand USD | 26.57% |
| 2016 | -1.01 Million USD | 30.65% |
| 2015 | -1.46 Million USD | -38.99% |
| 2014 | -1.05 Million USD | 2.77% |
| 2013 | -1.08 Million USD | 38.96% |
| 2012 | -1.77 Million USD | -101.36% |
| 2011 | -882 Thousand USD | 26.87% |
| 2010 | -1.2 Million USD | -154.97% |
| 2009 | -473 Thousand USD | 11.26% |
| 2008 | -533 Thousand USD | -513.18% |
| 2007 | 129 Thousand USD | 137.72% |
| 2006 | -342 Thousand USD | -149.42% |
| 2005 | 692 Thousand USD | 178.37% |
| 2004 | -883 Thousand USD | -669.68% |
| 2003 | 155 Thousand USD | -54.55% |
| 2002 | 341 Thousand USD | -12.56% |
| 2001 | 390 Thousand USD | -69.41% |
| 2000 | 1.27 Million USD | 27.5% |
| 1999 | 1 Million USD | 42.86% |
| 1998 | 700 Thousand USD | 40.0% |
| 1997 | 500 Thousand USD | 150.0% |
| 1996 | 200 Thousand USD | -93.94% |
| 1995 | 3.3 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -26 Thousand USD | -420.0% |
| 2024 Q2 | -19 Thousand USD | 261.54% |
| 2023 Q4 | -5000.00 USD | -131.25% |
| 2023 Q2 | -49 Thousand USD | -40.0% |
| 2023 Q3 | 16 Thousand USD | 132.65% |
| 2023 Q1 | -35 Thousand USD | 99.82% |
| 2023 FY | -78 Thousand USD | 99.61% |
| 2022 Q1 | -44 Thousand USD | 65.08% |
| 2022 FY | -19.78 Million USD | -2666.71% |
| 2022 Q4 | -19.72 Million USD | -203.4% |
| 2022 Q3 | -6.5 Million USD | -16566.67% |
| 2022 Q2 | -39 Thousand USD | 11.36% |
| 2021 Q3 | -124 Thousand USD | 51.56% |
| 2021 FY | -715 Thousand USD | -11.2% |
| 2021 Q4 | -126 Thousand USD | -1.61% |
| 2021 Q1 | -209 Thousand USD | -33.97% |
| 2021 Q2 | -256 Thousand USD | -22.49% |
| 2020 Q2 | -160 Thousand USD | -0.63% |
| 2020 Q4 | -156 Thousand USD | 7.14% |
| 2020 Q3 | -168 Thousand USD | -5.0% |
| 2020 FY | -643 Thousand USD | 14.61% |
| 2020 Q1 | -159 Thousand USD | 4.79% |
| 2019 Q2 | -186 Thousand USD | 19.48% |
| 2019 Q3 | -169 Thousand USD | 9.14% |
| 2019 FY | -753 Thousand USD | -45.65% |
| 2019 Q4 | -167 Thousand USD | 1.18% |
| 2019 Q1 | -231 Thousand USD | -450.0% |
| 2018 Q3 | -170 Thousand USD | -11.11% |
| 2018 Q1 | -152 Thousand USD | 38.21% |
| 2018 Q4 | -42 Thousand USD | 75.29% |
| 2018 FY | -517 Thousand USD | 30.7% |
| 2018 Q2 | -153 Thousand USD | -0.66% |
| 2017 Q2 | -5000.00 USD | 97.31% |
| 2017 Q4 | -246 Thousand USD | 20.39% |
| 2017 Q1 | -186 Thousand USD | 29.01% |
| 2017 FY | -746 Thousand USD | 26.57% |
| 2017 Q3 | -309 Thousand USD | -6080.0% |
| 2016 FY | -1.01 Million USD | 30.65% |
| 2016 Q1 | -229 Thousand USD | 32.45% |
| 2016 Q2 | -275 Thousand USD | -20.09% |
| 2016 Q3 | -250 Thousand USD | 9.09% |
| 2016 Q4 | -262 Thousand USD | -4.8% |
| 2015 Q3 | -330 Thousand USD | 28.26% |
| 2015 Q1 | -336 Thousand USD | -16.67% |
| 2015 Q4 | -339 Thousand USD | -2.73% |
| 2015 Q2 | -460 Thousand USD | -36.9% |
| 2015 FY | -1.46 Million USD | -38.99% |
| 2014 Q1 | -247 Thousand USD | -105.83% |
| 2014 Q4 | -288 Thousand USD | -10.34% |
| 2014 FY | -1.05 Million USD | 2.77% |
| 2014 Q2 | -258 Thousand USD | -4.45% |
| 2014 Q3 | -261 Thousand USD | -1.16% |
| 2013 Q1 | -149 Thousand USD | 67.61% |
| 2013 Q4 | -120 Thousand USD | 44.44% |
| 2013 FY | -1.08 Million USD | 38.96% |
| 2013 Q3 | -216 Thousand USD | 63.94% |
| 2013 Q2 | -599 Thousand USD | -302.01% |
| 2012 Q3 | -949 Thousand USD | -496.86% |
| 2012 Q2 | -159 Thousand USD | 23.56% |
| 2012 Q1 | -208 Thousand USD | 46.8% |
| 2012 Q4 | -460 Thousand USD | 51.53% |
| 2012 FY | -1.77 Million USD | -101.36% |
| 2011 Q3 | -172 Thousand USD | -2.38% |
| 2011 Q2 | -168 Thousand USD | -11.26% |
| 2011 Q1 | -151 Thousand USD | 77.29% |
| 2011 FY | -882 Thousand USD | 26.87% |
| 2011 Q4 | -391 Thousand USD | -127.33% |
| 2010 Q2 | -287 Thousand USD | -165.74% |
| 2010 Q3 | -146 Thousand USD | 49.13% |
| 2010 Q4 | -665 Thousand USD | -355.48% |
| 2010 Q1 | -108 Thousand USD | 13.6% |
| 2010 FY | -1.2 Million USD | -154.97% |
| 2009 Q4 | -125 Thousand USD | -3.31% |
| 2009 FY | -473 Thousand USD | 11.26% |
| 2009 Q1 | -92 Thousand USD | 29.23% |
| 2009 Q2 | -135 Thousand USD | -46.74% |
| 2009 Q3 | -121 Thousand USD | 10.37% |
| 2008 FY | -533 Thousand USD | -513.18% |
| 2008 Q4 | -130 Thousand USD | 28.57% |
| 2008 Q3 | -182 Thousand USD | -1.11% |
| 2008 Q1 | -41 Thousand USD | -133.61% |
| 2008 Q2 | -180 Thousand USD | -339.02% |
| 2007 Q2 | -81 Thousand USD | -526.32% |
| 2007 Q3 | 69 Thousand USD | 185.19% |
| 2007 Q1 | 19 Thousand USD | 136.54% |
| 2007 Q4 | 122 Thousand USD | 76.81% |
| 2007 FY | 129 Thousand USD | 137.72% |
| 2006 Q3 | -76 Thousand USD | 49.67% |
| 2006 FY | -342 Thousand USD | -149.42% |
| 2006 Q2 | -151 Thousand USD | -139.68% |
| 2006 Q4 | -52 Thousand USD | 31.58% |
| 2006 Q1 | -63 Thousand USD | -140.13% |
| 2005 Q1 | 160 Thousand USD | -20.4% |
| 2005 Q4 | 157 Thousand USD | -11.8% |
| 2005 FY | 692 Thousand USD | 178.37% |
| 2005 Q2 | 197 Thousand USD | 23.13% |
| 2005 Q3 | 178 Thousand USD | -9.64% |
| 2004 FY | -883 Thousand USD | -669.68% |
| 2004 Q1 | -293 Thousand USD | -1272.0% |
| 2004 Q2 | -361 Thousand USD | -23.21% |
| 2004 Q3 | -441 Thousand USD | -22.16% |
| 2004 Q4 | 201 Thousand USD | 145.58% |
| 2003 FY | 155 Thousand USD | -54.55% |
| 2003 Q4 | 25 Thousand USD | -80.0% |
| 2003 Q3 | 125 Thousand USD | 119.3% |
| 2003 Q1 | -52 Thousand USD | 89.28% |
| 2003 Q2 | 57 Thousand USD | 209.62% |
| 2002 Q1 | 613 Thousand USD | 612.79% |
| 2002 Q4 | -485 Thousand USD | -713.92% |
| 2002 Q3 | 79 Thousand USD | -41.04% |
| 2002 Q2 | 134 Thousand USD | -78.14% |
| 2002 FY | 341 Thousand USD | -12.56% |
| 2001 Q2 | 101 Thousand USD | -37.65% |
| 2001 Q3 | 76 Thousand USD | -24.75% |
| 2001 Q4 | 86 Thousand USD | 13.16% |
| 2001 FY | 390 Thousand USD | -69.41% |
| 2001 Q1 | 162 Thousand USD | -46.17% |
| 2000 Q3 | 353.84 Thousand USD | 11.48% |
| 2000 FY | 1.27 Million USD | 27.5% |
| 2000 Q2 | 317.4 Thousand USD | -20.71% |
| 2000 Q1 | 400.31 Thousand USD | 33.44% |
| 2000 Q4 | 300.94 Thousand USD | -14.95% |
| 1999 FY | 1 Million USD | 42.86% |
| 1999 Q4 | 300 Thousand USD | 0.0% |
| 1999 Q3 | 300 Thousand USD | 50.0% |
| 1999 Q2 | 200 Thousand USD | 0.0% |
| 1999 Q1 | 200 Thousand USD | 100.0% |
| 1998 Q1 | 200 Thousand USD | 0.0% |
| 1998 Q2 | 100 Thousand USD | -50.0% |
| 1998 Q3 | 200 Thousand USD | 100.0% |
| 1998 FY | 700 Thousand USD | 40.0% |
| 1998 Q4 | 100 Thousand USD | -50.0% |
| 1997 Q2 | 200 Thousand USD | 100.0% |
| 1997 Q3 | 100 Thousand USD | -50.0% |
| 1997 FY | 500 Thousand USD | 150.0% |
| 1997 Q4 | 200 Thousand USD | 100.0% |
| 1997 Q1 | 100 Thousand USD | 0.0% |
| 1996 Q1 | 100 Thousand USD | -88.89% |
| 1996 Q4 | - USD | -100.0% |
| 1996 FY | 200 Thousand USD | -93.94% |
| 1996 Q3 | 200 Thousand USD | 100.0% |
| 1996 Q2 | 100 Thousand USD | 0.0% |
| 1995 Q4 | 900 Thousand USD | 28.57% |
| 1995 Q3 | 700 Thousand USD | 0.0% |
| 1995 Q1 | 700 Thousand USD | 0.0% |
| 1995 Q2 | 700 Thousand USD | 0.0% |
| 1995 FY | 3.3 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 164.0% |
| Armata Pharmaceuticals, Inc. | -29.24 Million USD | 100.547% |
| Actinium Pharmaceuticals, Inc. | -709 Thousand USD | 122.567% |
| Azitra, Inc. | 260.45 Thousand USD | 38.568% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | 78.466% |
| Chromocell Therapeutics Corporation | -2.57 Million USD | 106.203% |
| Calidi Biotherapeutics, Inc. | -1.25 Million USD | 112.739% |
| CEL-SCI Corporation | -3.95 Million USD | 104.042% |
| iBio, Inc. | -1.02 Million USD | 115.61% |
| Lineage Cell Therapeutics, Inc. | 8.27 Million USD | 98.066% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | -13.39 Million USD | 101.195% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | 234.121% |
| NovaBay Pharmaceuticals, Inc. | 7.89 Million USD | 97.973% |
| NanoViricides, Inc. | -759.01 Thousand USD | 121.08% |
| Oragenics, Inc. | -15.45 Million USD | 101.035% |
| BiomX Inc. | -1.22 Million USD | 113.029% |
| BiomX Inc. | -1.22 Million USD | 113.029% |
| Protalix BioTherapeutics, Inc. | 42.51 Million USD | 99.624% |
| Palatin Technologies, Inc. | 4.39 Million USD | 96.357% |
| Scorpius Holdings, Inc. | -2.21 Million USD | 107.219% |